Cannabinoid-based drugs as anti-inflammatory therapeutics

By T. Klein. Nature reviews. Immunology, 2005

739 citations recorded by the source corpus.

Subfields: Nutrition and Dietetics, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/311c7dd975ce6ad2385c34c792b81f81abba03a8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Nutrition and Dietetics

1. V. Di Marzo

In Pharmacology

1. V. Di Marzo
2. George Kunos
3. P. Pacher
4. S. Batkai

In Surgery

1. P. Pacher
2. S. Batkai
3. George Kunos
4. V. Di Marzo

Citations in the corpus

• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “Multiple lines of evidence support the important role of the cannabinoid signaling system in the modulation of immune function and inflammation (reviewed in Klein et al., 1998, 2003; Walter and Stella, 2004; Klein, 2005).”
• Targeting the endocannabinoid system: to enhance or reduce? (2008, background): “Indeed, the use of CB 2 receptor antagonists against allergic contact dermatitis or multiple sclerosis might be limited by the fact that endocannabinoids do not only contribute to inflammation with chemotaxic effects, but can also inhibit inflammatory cytokine releas”
• Beta-caryophyllene is a dietary cannabinoid (2008, background): “In addition to a wide range of primarily CB1 receptor-mediated physiological effects on the central nervous system, different cannabinoid ligands have been reported to modulate immune responses (14).”